Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Nucleic acid aptamers have emerged as versatile molecular recognition tools that complement antibodies in diagnostics, therapeutics, and biotechnology. With precise three-dimensional folding and high-affinity binding, they can target small molecules, proteins, cells, and even viruses. At Creative Biogene, we offer a comprehensive aptamer development platform that spans library design, SELEX screening, optimization, synthesis, validation, and application development—helping transform aptamer technology into practical solutions for research and clinical innovation.
Figure 1. Overview of aptamer structure, showing sequence folding for target binding and the four main secondary structures. (Mayol B, et al., 2025)
Aptamers are short single-stranded DNA or RNA molecules generated through SELEX (Systematic Evolution of Ligands by EXponential enrichment). Their complex folding enables high-affinity binding via hydrogen bonding and electrostatic or hydrophobic interactions. Compared with antibodies, aptamers offer faster production without animal immunization, flexible chemical modification, strong stability, low immunogenicity, and better tissue penetration—ideal for biosensors, biomarker assays, targeted delivery, and imaging.
Table 1. Global Representative Nucleic Acid Aptamer Drug Development Progress
RNA
DNA
| Year | Drug Name | Target | Development Stage | Company / Institution |
| 2004 | Macugen (Pegaptanib, EYE001) | VEGF165 | Approved (FDA) | Eyetech Pharmaceuticals / Pfizer |
| 2010 | ARC1905 (Zimura) | C5 | Phase III completed (NDA submission planned for 2025) | IVERIC bio / Astellas |
| 2012 | Nox-E36 | MCP-1 (CCL2) | Phase II completed | TME Pharma AG |
| 2012 | Nox-A12 (Olaptesed pegol) | SDF-1 (CXCL12) | Phase II ongoing (in combination with immunotherapy) | TME Pharma AG |
| 2013 | Nox-H94 (Lexaptepid pegol) | Hepcidin | Phase II completed | TME Pharma AG |
| 2015 | BT200 (Bemosiran) | vWF A1 domain | Phase II ongoing | Aptarion Biotech AG |
| 2016 | NU172 | Thrombin | Phase II completed | ARCA Biopharma |
| 2019 | AON-D21 | C5a | Phase I completed | Aptarion Biotech AG |
| 2022 | APTABIO-FXa | Factor Xa | Preclinical | Aptamer Group Ltd |
| 2023 | Avacincaptad pegol (IZERVAY) | C5 (Complement system) | Approved (FDA 2023) | IVERIC bio / Astellas |
| 2024 | BT500 Series | P-selectin / vWF dual target | Preclinical (IND preparation) | Aptarion Biotech AG |
| 2025 | Nox-A12 + Radiation combo | CXCL12 (with immunoradiotherapy) | Phase II/III registrational trial ongoing | TME Pharma AG |
| Year | Drug Name | Target | Development Stage | Company / Institution |
| 2008 | ARC1779 | vWF | Phase II completed | Archemix Corp |
| 2016 | 6Ga-Sgc8 | PTK7 | Phase I completed | Xijing Hospital |
| 2018 | APTOLL | TLR4 | Phase II ongoing (Europe Phase IIb GATEWAY trial) | aptaTargets SL |
| 2020 | ADHERE (BC007) | Autoantibody / GPCR | Phase II ongoing (Germany) | Berlin Cures GmbH |
| 2021 | BNT007 | SARS-CoV-2 Spike protein | Preclinical completed | BioNTech SE |
Advances in next-generation sequencing, computational modeling, and chemical modification have enhanced selection efficiency and in vivo stability, driving aptamer use in both fundamental research and clinical applications.
Creative Biogene's platform provides end-to-end solutions for aptamer screening and optimization. We design and synthesize random or semi-random oligonucleotide libraries with up to 1015 variants to maximize diversity. Depending on project goals, we employ classical SELEX, Cell-SELEX, Capture-SELEX, or Hybrid-SELEX, combining iterative selection with negative and competitive enrichment to ensure specificity.
We support a wide variety of targets—from proteins and peptides to metabolites, receptors, and metal ions—and use high-throughput sequencing (NGS) and bioinformatics to identify high-potential sequences early, shortening discovery time and improving success rates.
Figure 2. Aptamer design. (Mayol B, et al., 2025)
Design Refinement
Computational folding and docking guide the adjustment of sequence length and structure for higher affinity and stability.
Chemical Enhancement
2′-F, 2′-O-Me, and LNA modifications enhance nuclease resistance and pharmacokinetics.
Functionalization
Aptamers can be labeled or conjugated with fluorophores, biotin, PEG, or nanoparticles to expand their use in sensing, delivery, and imaging.
We validate binding through SPR, BLI, ITC, fluorescence, or electrochemical assays, confirming affinity, kinetics, and specificity. Structural stability is assessed under enzymatic or thermal stress, and reproducibility is tested across multiple cycles.
For biological validation, we provide cell-based and in vivo testing to evaluate uptake and target engagement, and assist in integrating aptamers into biosensors, diagnostic kits, or capture systems.
Creative Biogene also offers:
Quality and Support:
A multidisciplinary team with expertise in nucleic acid chemistry, molecular biology, and bioinformatics backs our services. Every step follows strict quality control—monitoring purity, amplification, binding kinetics, and reproducibility. Automation and high-throughput instruments ensure speed and consistency. We guarantee confidentiality, IP protection, and transparent reporting, along with continued technical support post-delivery.
Creative Biogene combines deep scientific expertise with flexible project design to deliver high-performance, application-ready aptamers. From concept to validation, we help clients achieve reliable, reproducible, and scalable solutions—advancing innovation across biotechnology, diagnostics, and precision medicine.
Copyright © Creative Biogene. All rights reserved.